312 related articles for article (PubMed ID: 17517521)
1. Virus inactivation by protein denaturants used in affinity chromatography.
Roberts PL; Lloyd D
Biologicals; 2007 Oct; 35(4):343-7. PubMed ID: 17517521
[TBL] [Abstract][Full Text] [Related]
2. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography.
Roberts PL; Walker CP; Feldman PA
Vox Sang; 1994; 67 Suppl 1():69-71. PubMed ID: 8091741
[TBL] [Abstract][Full Text] [Related]
3. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII.
Roberts PL
Biologicals; 2008 Sep; 36(5):330-5. PubMed ID: 18674928
[TBL] [Abstract][Full Text] [Related]
4. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of adenovirus type 5 by caustics.
Jannat R; Hsu D; Maheshwari G
Biotechnol Prog; 2005; 21(2):446-50. PubMed ID: 15801784
[TBL] [Abstract][Full Text] [Related]
6. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
7. Validation of a viral and bacterial inactivation step during the extraction and purification process of porcine collagen.
Forest P; Morfin F; Bergeron E; Dore J; Bensa S; Wittmann C; Picot S; Renaud FN; Freney J; Gagnieu C
Biomed Mater Eng; 2007; 17(4):199-208. PubMed ID: 17611295
[TBL] [Abstract][Full Text] [Related]
8. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products.
Remington KM; Trejo SR; Buczynski G; Li H; Osheroff WP; Brown JP; Renfrow H; Reynolds R; Pifat DY
Vox Sang; 2004 Jul; 87(1):10-8. PubMed ID: 15260817
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of enveloped and non-enveloped viruses in the process of chemical treatment and gamma irradiation of bovine-derived grafting materials.
Lee KI; Lee JS; Jung HH; Lee HY; Moon SH; Kang KT; Shim YB; Jang JW
Xenotransplantation; 2012; 19(6):365-9. PubMed ID: 23198732
[TBL] [Abstract][Full Text] [Related]
11. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
Roberts P
Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
[TBL] [Abstract][Full Text] [Related]
12. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
13. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
Roberts PL; Dunkerley C; McAuley A; Winkelman L
Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
[TBL] [Abstract][Full Text] [Related]
14. Effects of several virucidal agents on inactivation of influenza, Newcastle disease, and avian infectious bronchitis viruses in the allantoic fluid of chicken eggs.
Abe M; Kaneko K; Ueda A; Otsuka H; Shiosaki K; Nozaki C; Goto S
Jpn J Infect Dis; 2007 Nov; 60(6):342-6. PubMed ID: 18032831
[TBL] [Abstract][Full Text] [Related]
15. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of herpes simplex type 1 gene vector on immobilized metal affinity chromatography: oxidative damage by hydroxyl free radicals and its prevention.
Jiang C; Ataai M; Ozuer A; Krisky D; Wechuck J; Pornsuwan S; Pourarian F; Glorioso JC
Biotechnol Bioeng; 2006 Sep; 95(1):48-57. PubMed ID: 16673413
[TBL] [Abstract][Full Text] [Related]
18. Resistance of surface-dried virus to common disinfection procedures.
Terpstra FG; van den Blink AE; Bos LM; Boots AG; Brinkhuis FH; Gijsen E; van Remmerden Y; Schuitemaker H; van 't Wout AB
J Hosp Infect; 2007 Aug; 66(4):332-8. PubMed ID: 17601636
[TBL] [Abstract][Full Text] [Related]
19. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
Borovec S; Broumis C; Adcock W; Fang R; Uren E
Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
[TBL] [Abstract][Full Text] [Related]
20. Viral inactivation of human bone tissue using supercritical fluid extraction.
Fages J; Poirier B; Barbier Y; Frayssinet P; Joffret ML; Majewski W; Bonel G; Larzul D
ASAIO J; 1998; 44(4):289-93. PubMed ID: 9682954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
